Tarsus Pharmaceuticals TARS
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
Tarsus Pharmaceuticals (TARS) Core Market Data and Business Metrics
Latest Closing Price
$51.49Price-Earnings Ratio
-16.77Total Outstanding Shares
41.61 Million SharesDividend
No dividendSIC Description
Biological Products, (no Disgnostic Substances)Primary Exchange
NASDAQHeadquarters
15440 Laguna Canyon Road, Irvine, CA, 92618
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 593,663 Shares | 12.47 | 3/14/2025 | 7,403,040 Shares |
| 791,300 Shares | 9.28 | 2/28/2025 | 7,342,164 Shares |
| 454,438 Shares | 15.59 | 2/14/2025 | 7,082,922 Shares |
| 460,777 Shares | 15.93 | 1/31/2025 | 7,339,031 Shares |
| 994,905 Shares | 7.06 | 1/15/2025 | 7,020,304 Shares |
| 520,937 Shares | 14.07 | 12/31/2024 | 7,328,028 Shares |
Cash Flow Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Net Cash Flow, Continuing | $-127.57 Million |
| Net Cash Flow From Operating Activities | $-83.03 Million |
| Net Cash Flow From Investing Activities, Continuing | $-199.19 Million |
| Net Cash Flow From Investing Activities | $-199.19 Million |
| Net Cash Flow From Financing Activities, Continuing | $154.66 Million |
| Net Cash Flow From Operating Activities, Continuing | $-83.03 Million |
Income Statement
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit, Deferred | $0 |
| Other Operating Expenses | $12.83 Million |
| Income Tax Expense/Benefit, Current | $0 |
| Research and Development | $53.39 Million |
| Selling, General, and Administrative Expenses | $237.31 Million |
| Operating Expenses | $303.52 Million |
Comprehensive Income
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss | $-115.37 Million |
| Other Comprehensive Income/Loss | $181,000 |
| Comprehensive Income/Loss Attributable To Parent | $-115.37 Million |
Balance Sheet
January 1, 2024 to December 31, 2024
| Metric | Value |
|---|---|
| Long-term Debt | $71.84 Million |
| Current Liabilities | $80.61 Million |
| Prepaid Expenses | $14.65 Million |
| Other Non-current Assets | $9.65 Million |
| Assets | $376.99 Million |
| Fixed Assets | $2.31 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||